| Holmium laser ablation of the prostate (HoLAP): intermediate-term results of 144 patients. | |
| | |
MedLine Citation:
|
PMID: 22782618 Owner: NLM Status: Publisher |
Abstract/OtherAbstract:
|
PURPOSE: To retrospectively analyse the intermediate-term outcome of holmium laser ablation of the prostate (HoLAP) of up to 4 years postoperatively in one of the largest series and to define the selection criteria for patients who benefit from potentially lower complications associated with HoLAP. METHODS: Between June 2006 and November 2010, 144 patients with benign prostatic obstruction were treated at two centres with standardised HoLAP (2.0 J/50 Hz or 3.2 J/25 Hz with Versapulse(®) 80-100 W laser Lumenis(®)). Median follow-up was 21 months (range, 1-54). International prostate symptom score and quality of life (IPSS-QoL), PSA, prostate volume, maximal flow rate (Qmax), postvoiding residual volume (Vres) were evaluated pre- and postoperatively. All complications were graded according to CTCAE (v4.03). RESULTS: Mean patient age was 70.1 ± 7.7 years (range, 46-90). With a preoperative median prostate volume of 40 ml (range, 10-130), the median operation time was 50 min (range, 9-138). We observed a median catheterisation time of 1 day (range, 0-12) and hospitalisation time of 2 days (range, 1-16). IPSS-QoL, Qmax and Vres were significantly improved after 3 months, and all parameters remained unchanged after 12, 24 and 36 months. The rate of re-operation was significantly lower in patients with prostate volume <40 ml, compared to patients with prostates ≥40 ml (9.1 vs. 25 %, p = 0.04). CONCLUSIONS: HoLAP is a safe and effective procedure for the treatment of prostates <40 ml. Patients benefit from HoLAP because of a low bleeding rate and short hospital stay. Due to high recurrence rates, HoLAP should be avoided in prostates >40 ml. |
| | |
Authors:
|
D Barski; M Richter; C Winter; C Arsov; P de Geeter; R Rabenalt; P Albers |
Related Documents
:
|
22558238 - Impact of natalizumab on cognitive performances and fatigue in relapsing multiple scler... 22622138 - Type iii procollagen-n-peptide as a predictor of persistent atrial fibrillation recurre... 22354738 - Does interferon beta treatment exacerbate neuromyelitis optica spectrum disorder? 22589638 - Functional outcome at 6 months in surgical treatment of spontaneous supratentorial intr... 22864648 - Impact of 22q11.2 deletion on the postoperative course of children after cardiac surgery. 20695188 - 18 months of experiences with the biotitanium replacement (implaspin) used in treatment... |
Publication Detail:
|
Type: JOURNAL ARTICLE Date: 2012-7-11 |
Journal Detail:
|
Title: World journal of urology Volume: - ISSN: 1433-8726 ISO Abbreviation: - Publication Date: 2012 Jul |
Date Detail:
|
Created Date: 2012-7-11 Completed Date: - Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 8307716 Medline TA: World J Urol Country: - |
Other Details:
|
Languages: ENG Pagination: - Citation Subset: - |
Affiliation:
|
Department of Urology, Duesseldorf University Hospital, Moorenstrasse 5, 40225, Düsseldorf, Germany, dimitri.barski@med.uni-duesseldorf.de. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
|
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Microbial transformation of the sesquiterpene lactone tagitinin C by the fungus Aspergillus terreus.
Next Document: Maximizing the potency of siRNA lipid nanoparticles for hepatic gene silencing in vivo.